CN Patent

CN1335771A — 作为趋化因子受体活性调节剂的n－脲基烷基－哌啶化合物

Assigned to Bristol Myers Squibb Pharma Co · Expires 2002-02-13 · 24y expired

What this patent protects

本申请描述了可用于预防气喘及其它变应性疾病的式(I)CCR3调节剂或其可药用盐形式。

USPTO Abstract

本申请描述了可用于预防气喘及其它变应性疾病的式(I)CCR3调节剂或其可药用盐形式。

Drugs covered by this patent

Patent Metadata

Patent number
CN1335771A
Jurisdiction
CN
Classification
—
Expires
2002-02-13
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Pharma Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.